DOP2023000247A - Moduladores de los receptores acoplados a proteínas g - Google Patents

Moduladores de los receptores acoplados a proteínas g

Info

Publication number
DOP2023000247A
DOP2023000247A DO2023000247A DO2023000247A DOP2023000247A DO P2023000247 A DOP2023000247 A DO P2023000247A DO 2023000247 A DO2023000247 A DO 2023000247A DO 2023000247 A DO2023000247 A DO 2023000247A DO P2023000247 A DOP2023000247 A DO P2023000247A
Authority
DO
Dominican Republic
Prior art keywords
chemical entities
modulators
protein
gipr
glp
Prior art date
Application number
DO2023000247A
Other languages
English (en)
Inventor
Erlanson Daniel
V Fucini Raymond
Hansen Stig
Iwig Jeff
Krishnan Shyam
Moya Enrique
Sethofer Steven
Original Assignee
Carmot Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carmot Therapeutics Inc filed Critical Carmot Therapeutics Inc
Publication of DOP2023000247A publication Critical patent/DOP2023000247A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Holo Graphy (AREA)
  • Gyroscopes (AREA)
  • Amplifiers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente divulgación presenta entidades químicas que modulan (por ejemplo, agonizan o agonizan parcialmente o antagonizan) el receptor del péptido 1 similar al glucagón (“GLP-1R”) y/o el receptor del polipéptido inhibidor gástrico (“GIPR”). Las entidades químicas son útiles, por ejemplo, para tratar una enfermedad, trastorno o afección en la que la modulación de las actividades de GLP-1R y/o GIPR es beneficiosa para el tratamiento o prevención de la patología subyacente y/o los síntomas y/o la progresión de la enfermedad, trastorno o condición. Esta divulgación también presenta composiciones así como otros métodos de uso y elaboración de dichas entidades químicas
DO2023000247A 2021-05-13 2023-11-09 Moduladores de los receptores acoplados a proteínas g DOP2023000247A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163188342P 2021-05-13 2021-05-13
PCT/US2022/029305 WO2022241287A2 (en) 2021-05-13 2022-05-13 Modulators of g-protein coupled receptors

Publications (1)

Publication Number Publication Date
DOP2023000247A true DOP2023000247A (es) 2024-03-28

Family

ID=82019613

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000247A DOP2023000247A (es) 2021-05-13 2023-11-09 Moduladores de los receptores acoplados a proteínas g

Country Status (17)

Country Link
US (1) US20230151074A1 (es)
EP (1) EP4337682A2 (es)
JP (1) JP2024517942A (es)
KR (1) KR20240007251A (es)
CN (1) CN117980325A (es)
AU (1) AU2022272251A1 (es)
BR (1) BR112023023559A2 (es)
CA (1) CA3220005A1 (es)
CL (1) CL2023003369A1 (es)
CO (1) CO2023015805A2 (es)
CR (1) CR20230530A (es)
DO (1) DOP2023000247A (es)
EC (1) ECSP23093673A (es)
IL (1) IL308392A (es)
PE (1) PE20240890A1 (es)
TW (1) TW202313666A (es)
WO (1) WO2022241287A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240007251A (ko) * 2021-05-13 2024-01-16 카모트 테라퓨틱스, 인크. G-단백질 결합 수용체의 조절제

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2002006234A1 (fr) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Derives de sulfonate, procede de production et utilisation de ces derives
AU2003278600A1 (en) 2002-11-01 2004-05-25 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
TW200523247A (en) 2003-12-25 2005-07-16 Takeda Pharmaceutical 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical PHENOXYALKANSÄUREVERBINDUNG
US8153694B2 (en) 2005-07-29 2012-04-10 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20080009530A1 (en) 2005-08-10 2008-01-10 Hidenori Abe Therapeutic Agent for Diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP2743268A3 (en) 2006-06-27 2014-10-08 Takeda Pharmaceutical Company Limited Fused cyclic compounds as GPR40 receptor modulators
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US7652133B2 (en) 2006-10-19 2010-01-26 Takeda Pharmaceutical Company Limited Indole compound
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
WO2008099794A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
EP2149550A4 (en) 2007-04-27 2010-08-11 Takeda Pharmaceutical HETEROCYCLIC COMPOUND WITH FIVE NITROGEN CHAINS
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
EP2952202B1 (en) 2008-06-17 2017-10-18 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
US20120021979A1 (en) 2010-06-24 2012-01-26 Vanderbilt University GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
IL277495B1 (en) * 2018-03-23 2024-04-01 Carmot Therapeutics Inc Modulators of protein-coupled receptors - G
KR20240007251A (ko) * 2021-05-13 2024-01-16 카모트 테라퓨틱스, 인크. G-단백질 결합 수용체의 조절제

Also Published As

Publication number Publication date
CN117980325A (zh) 2024-05-03
CR20230530A (es) 2024-02-19
CO2023015805A2 (es) 2023-12-11
ECSP23093673A (es) 2024-01-31
IL308392A (en) 2024-01-01
WO2022241287A2 (en) 2022-11-17
US20230151074A1 (en) 2023-05-18
CL2023003369A1 (es) 2024-05-17
CA3220005A1 (en) 2022-11-17
KR20240007251A (ko) 2024-01-16
AU2022272251A1 (en) 2023-11-16
TW202313666A (zh) 2023-04-01
JP2024517942A (ja) 2024-04-23
BR112023023559A2 (pt) 2024-02-06
EP4337682A2 (en) 2024-03-20
WO2022241287A3 (en) 2022-12-29
PE20240890A1 (es) 2024-04-24

Similar Documents

Publication Publication Date Title
DOP2023000247A (es) Moduladores de los receptores acoplados a proteínas g
AR115016A1 (es) Moduladores de receptores acoplados a la proteína g
CL2022001030A1 (es) Compuestos moduladores de glp-1r
CL2019002314A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
ES2533242T3 (es) Prevención y tratamiento de afecciones oculares asociadas con el complemento
CL2022001271A1 (es) Agonista del receptor glp-1 y uso de este
CL2019002112A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
ECSP21000999A (es) Modificaciones de cristales de odevixibat
PE20211977A1 (es) Receptores de antigenos quimericos de gprc5d y celulas que los expresan
ECSP19055169A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
DOP2023000231A (es) Compuestos carboxi-benzimidazol moduladores de glp-1r
UY32883A (es) Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano
ECSP024346A (es) Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
PE20180158A1 (es) Coagonistas de los receptores de glucagon y de glp-1
PE20091674A1 (es) Antagonistas del receptor de glucagon
DOP2019000106A (es) Compuestos del péptido tirosina tirosina cíclico como moduladores de receptores de neuropéptido y
AR110394A1 (es) Estructura del cristal de gremlin-1 y anticuerpo inhibidor
PE20211417A1 (es) Analogos novedosos de glp-1
CL2020002165A1 (es) Uso de tradipitant para tratar la cinetosis.
AR122104A1 (es) ANTICUERPOS DE DOMINIO SIMPLE VHH CONTRA EL VIRUS SARS-CoV-2 Y MÉTODO RÁPIDO DE OBTENCIÓN DE VHH
AR112291A1 (es) Composición para su uso en la prevención y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncológico
AR112760A1 (es) Compuestos bifuncionales que comprenden un análogo de glp-1 y un análogo de egf(a)
PE20231029A1 (es) ANTICUERPO BIESPECIFICO CONTRA (alfa)-SYN/IGF1R Y USO DEL MISMO
BR112023005152A2 (pt) Anticorpo biespecífico com especificidade intensificada (seba)
EA200500516A1 (ru) Замещённые тетралины и инданы и их применение